Zheng Su

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. pmc MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
    Heleen Scheerens
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080, USA
    Arthritis Res Ther 13:R177. 2011
  2. doi An adaptive design for phase II non-oncology dose selection clinical trials
    Zheng Su
    Genentech Inc, South San Francisco, California, USA
    Clin Drug Investig 30:397-403. 2010
  3. doi Balancing multiple baseline characteristics in randomized clinical trials
    Zheng Su
    Senior Statistician, Genentech Inc, South San Francisco, CA 94080, USA
    Contemp Clin Trials 32:547-50. 2011
  4. doi A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities
    Zheng Su
    Genentech Inc, CA 94080, USA
    Contemp Clin Trials 31:105-7. 2010
  5. doi Assessing the success probability of a Phase III clinical trial based on Phase II data
    Zheng Su
    Department of Biostatistics, Genentech Inc, Mail Stop 451b, 1 DNA Way, South San Francisco, CA 94080, USA
    Contemp Clin Trials 31:620-3. 2010
  6. doi Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach
    Jing Yi
    Genentech Inc, South San Francisco, CA 94080, USA
    Contemp Clin Trials 33:138-42. 2012
  7. ncbi An optimization algorithm for designing phase I cancer clinical trials
    Hui Jiang
    Institute for Computational and Mathematical Engineering, Stanford University, Stanford, California, USA
    Contemp Clin Trials 29:102-8. 2008

Collaborators

  • Jing Yi
  • Liang Fang
  • Heleen Scheerens
  • Hui Jiang
  • Bryan Irving
  • Eric Stefanich
  • John C Davis
  • Yanan Zheng
  • Michael J Townsend
  • Clifton O Bingham
  • Vishala Chindalore
  • Yifan Liu

Detail Information

Publications7

  1. pmc MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
    Heleen Scheerens
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080, USA
    Arthritis Res Ther 13:R177. 2011
    ....
  2. doi An adaptive design for phase II non-oncology dose selection clinical trials
    Zheng Su
    Genentech Inc, South San Francisco, California, USA
    Clin Drug Investig 30:397-403. 2010
    ..The proposed adaptive design should be preferred over the standard design especially in cases where enrolment is slow and efficacy can be measured after a relatively short period of time...
  3. doi Balancing multiple baseline characteristics in randomized clinical trials
    Zheng Su
    Senior Statistician, Genentech Inc, South San Francisco, CA 94080, USA
    Contemp Clin Trials 32:547-50. 2011
    ..The proposed randomization method can be easily implemented and generalized for cases where there are multiple treatment arms with equal or unequal randomization probabilities...
  4. doi A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities
    Zheng Su
    Genentech Inc, CA 94080, USA
    Contemp Clin Trials 31:105-7. 2010
    ..It starts with a modified CRM approach in the first stage and makes use of the accumulated data from the first stage to provide likelihood estimates of model parameters for use in the second stage...
  5. doi Assessing the success probability of a Phase III clinical trial based on Phase II data
    Zheng Su
    Department of Biostatistics, Genentech Inc, Mail Stop 451b, 1 DNA Way, South San Francisco, CA 94080, USA
    Contemp Clin Trials 31:620-3. 2010
    ....
  6. doi Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach
    Jing Yi
    Genentech Inc, South San Francisco, CA 94080, USA
    Contemp Clin Trials 33:138-42. 2012
    ..In addition, it does not resort to asymptotics and applies to general test statistics of either single or multiple dimensions...
  7. ncbi An optimization algorithm for designing phase I cancer clinical trials
    Hui Jiang
    Institute for Computational and Mathematical Engineering, Stanford University, Stanford, California, USA
    Contemp Clin Trials 29:102-8. 2008
    ..It searches for an approximately optimal design within a design space, in which the 3+3 design is included as a special case. Simulation studies show that the design recommended by this algorithm significantly outperforms the 3+3 design...